2018
The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities
Cortesi P, Belli L, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani L, Strazzabosco M, Association T. The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities. Journal Of Viral Hepatitis 2018, 25: 791-801. PMID: 29406608, DOI: 10.1111/jvh.12877.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaDCC patientsTreatment strategiesIntestine Transplant AssociationProgression of HCVTransplant-eligible patientsHepatitis C therapyTransplant-related factorsCohort of patientsTime of transplantationDecision analytical modelCost-effectiveness analysisDAA effectivenessDAA treatmentEuropean LiverHCC presencePre-LTMELD scoreC therapyCirrhotic patientsDisease recurrenceTransplant centersSpecific regimenTransplant AssociationPatient level
2014
Characterization of animal models for primary sclerosing cholangitis (PSC)
Fickert P, Pollheimer MJ, Beuers U, Lackner C, Hirschfield G, Housset C, Keitel V, Schramm C, Marschall HU, Karlsen TH, Melum E, Kaser A, Eksteen B, Strazzabosco M, Manns M, Trauner M, Group I. Characterization of animal models for primary sclerosing cholangitis (PSC). Journal Of Hepatology 2014, 60: 1290-1303. PMID: 24560657, PMCID: PMC4517670, DOI: 10.1016/j.jhep.2014.02.006.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisAnimal modelsEnd-stage liver diseaseStage liver diseaseDevelopment of cholestasisNew treatment strategiesEffective medical treatmentLiver transplantationSclerosing cholangitisBiliary fibrosisChronic cholangiopathiesLiver diseaseTreatment strategiesStudy groupHigh riskPathogenetic conceptsMedical treatmentFrequent needCholangitisCholangiopathyCholestasisPoor understandingTransplantationFibrosisGroup